Enveric Biosciences, Inc.
ENVB
$5.32
$0.224.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.11% | 25.62% | -15.30% | 30.74% | -51.37% |
| Total Depreciation and Amortization | -2.23% | 1.00% | -50.62% | -1.82% | -2.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 362.61% | -71.74% | 7.84% | -78.34% | 138.60% |
| Change in Net Operating Assets | 133.37% | -178.37% | 179.93% | -154.59% | 24.99% |
| Cash from Operations | 13.98% | -9.78% | 20.97% | -82.36% | -41.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -10.14% | 566.31% | -89.91% | 819.57% | -6.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -20,300.00% |
| Cash from Financing | -10.14% | 566.31% | -89.91% | 860.06% | -10.49% |
| Foreign Exchange rate Adjustments | 262.50% | -166.67% | 7.69% | 82.74% | -222.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.33% | 162.84% | -170.35% | 335.83% | -122.74% |